Patent Document ID: 8399206
Application ID: 12910769
Patent Flag: 1

Claim One:
1. A method of diagnosing, prognosing, determining progression, predicting a response to a treatment or choosing a treatment in an individual having acute myeloid leukemia (AML), said method comprising: analyzing single cells from a sample from the individual, comprising one or more AML cells, by a method comprising: a) separately contacting the cells with the following three modulators in separate wells: PMA, SCF, and FLT3L; b) determining an activation level of three of the following four activatable elements for each sample of cells: p-Erk, p-Creb, p-S6, and p-AKT; and c) classifying said one or more AML cells from the individual into groups comprising: risk of relapse, response or non-response to therapeutic treatment based on the activation levels of the three activatable elements, said classification enabling a decision regarding a diagnosis, prognosis, progression, response to a treatment or a selection of treatment for the individual based on said classification of said one or more AML cells.